A STUDY OF METHOD DEVELOPMENT, VALIDATION AND FORCED DEGRADATION FOR SIMULTANEOUS QUANTIFICATION OF CABOZANTINIB AND NIVOLUMAB IN BULK AND PHARMACEUTICAL DOSAGE FORM BY RP-HPLC
Objective: The present paper describes a simple, accurate, and precise reversed-phase high-performance liquid chromatography (HPLC) method for rapid and simultaneous quantification of cabozantinib (CZT) and nivolumab (NVM) in bulk and pharmaceutical dosage form.
Methods: The chromatographic separation was achieved on Luna C18 (150 mm×4.6 mm, 3.5 μm). Mobile phase contained a mixture of 0.1% orthophosphoric acid and acetonitrile in the ratio of 50:50 v/v, flow rate 1.0 ml/min, and ultraviolet detection at 222 nm.
Results: The proposed method shows a good linearity in the concentration range of 20–300 μg/ml for CZT and 5–75 μg/ml for NVM under optimized conditions. Precision and recovery study results are in between 98 and 102%. In the entire robustness conditions, percentage relative standard deviation is <2.0%. Degradation has minimum effect in stress condition and solutions are stable up to 24 h.
Conclusion: This method is validated for different parameters such as precision, linearity, accuracy, limit of detection (LOD), limit of quantification (LOQ), ruggedness, robustness, and forced degradation study were determined according to the International Conference of Harmonization (ICH) Q2B guidelines. All the parameters of validation were found to be within the acceptance range of ICH guidelines. Since there is no HPLC method reported in the literature for the estimation of CZT and NVM in pharmaceutical dosage forms, there is a need to develop quantitative methods under different conditions to achieve improvement in sensitivity, selectivity, etc.
The author declares the interest to develop a validation and forced degradation for simultaneous quantification of CZT and NVM.
2. Curti B, Jana B, Mandal RN. Renal cell carcinoma. Medscape 2014;14:248-62.
3. Bruce A, Bray D, Lewis J, Raff M. Molecular biology of the cell. Graland Sci 1996;6:1-10.
4. Hanks SK, Quinn AM, Hunter T. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 1988;241:42-52.
5. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
6. Galland F, Stefanova M, Lafage M, Birnbaum D. Localization of the 5’ end of the MCF2 oncogene to human chromosome 15q15-q23. Cytogenet Cell Genet 1992;60:114-6.
7. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19:2003-12.
8. O’Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, et al. Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 1991;11:5016-31.
9. Ellis A, Dryden W, Bond FW. Reason and Emotion in Psychotherapy: Comprehensive Method of Treating Human Disturbances. New York: Carol Publishing Group; 1994.
10. Carthy M, Alice A, et al. Evelix’s integrated drug-discovery and development platform for human therapeutics. Chem Biol 2005;12:407-8.
11. World Health Organization. WHO Drug information. Vol. 26. North York: World Health Organization; 2012. p. 2.
12. National Cancer Institute. Melanoma Treatment-for Health Professionals. United States: National Cancer Institute; 2015.
13. Yervoy, ipilimumab-Product profile-Bio Century. Bio Century Online Intelligence. New York: Bio Century Publications; 2012.
14. Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: Latest evidence and clinical potential. Ther Adv Med Oncol 2015;7:97-106.
15. Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: Latest evidence and clinical potential. Ther Adv Med Oncol 2015;7:85-96.
16. Farlex. Partner Medical Dictionary. Huntingdon valley: Farlex; 2012.
17. Large Intestine. Encyclopedia Britannica. Chicago: WENTWORTH Press; 2016.
18. Junqueria LC, Carneiro J. Basic Histology. Brazil: Mc Graw-Hill; 2003.
19. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010;236:219-42.
20. Harry V.Galboin, Cytochrome P450 mediated drug and carcinogen metabolism using monocloanl antibodies. Avaliable from: https://home.ccr.cancer.gov/metabolism/hvgccr.htm
21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.
22. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. Molecular Biology of the Cell. New York: Graland Science; 2002. p. 1367.
23. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342:1432-3.
24. US SEC, Form 10-K Bristol-Myers Squibb Company. U.S. Securities and Exchange Commission. Bristo-Myers squibb company, Newyork.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.